ultra-rapid-acting recombinant human insulin (BIOD-123) - Albireo
BIOD-250 - Albireo
BIOD-238 - Albireo
Biodel: JMP Securities Healthcare Conference (Biodel) - Jul 12, 2013 - Anticipated intellectual property protection in EU through 2025; Anticipated intellectual property protection in US through 2026 
Anticipated patent expiry • Diabetes
http://investor.biodel.com/events.cfm
 
Jul 12, 2013
 
.